MA51893A - Ligands de gm-csf ou du récepteur gm-csf destinés à être utilisés dans le traitement d'une malignité hématologique chez un patient ayant subi un allo-hct - Google Patents
Ligands de gm-csf ou du récepteur gm-csf destinés à être utilisés dans le traitement d'une malignité hématologique chez un patient ayant subi un allo-hctInfo
- Publication number
- MA51893A MA51893A MA051893A MA51893A MA51893A MA 51893 A MA51893 A MA 51893A MA 051893 A MA051893 A MA 051893A MA 51893 A MA51893 A MA 51893A MA 51893 A MA51893 A MA 51893A
- Authority
- MA
- Morocco
- Prior art keywords
- csf
- malignity
- allo
- hct
- hematological
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18158169 | 2018-02-22 | ||
| EP18189562 | 2018-08-17 | ||
| EP18194549.4A EP3623382A1 (en) | 2018-09-14 | 2018-09-14 | Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct |
| US16/269,572 US11655293B2 (en) | 2018-02-22 | 2019-02-07 | Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51893A true MA51893A (fr) | 2020-12-30 |
Family
ID=67616687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051893A MA51893A (fr) | 2018-02-22 | 2019-02-22 | Ligands de gm-csf ou du récepteur gm-csf destinés à être utilisés dans le traitement d'une malignité hématologique chez un patient ayant subi un allo-hct |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11655293B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3755715A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7278296B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200123434A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111886248B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019224550A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020017253A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3091536A1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA51893A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2020008792A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019162472A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11655293B2 (en) | 2018-02-22 | 2023-05-23 | Universitat Zurich | Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT |
| MX2022011111A (es) * | 2020-03-08 | 2023-03-02 | Humanigen Inc | Métodos para tratar infección de coronavirus y lesión pulmonar inducida por inflamación resultante. |
| TW202317637A (zh) * | 2021-08-26 | 2023-05-01 | 日商協和麒麟股份有限公司 | 與cd116及cd131結合之雙特異性抗體 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0009772A (pt) | 1999-04-14 | 2002-01-08 | Us Health | Composições contendo imunotoxinas e agentes que inibem a maturação de células dendrìticas para induzir tolerância imune a um enxerto |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| ES2918209T3 (es) | 2005-05-18 | 2022-07-14 | Morphosys Ag | Anticuerpos anti-GM-CSF y usos a partir de los mismos |
| JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトgm−csfに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| KR101395515B1 (ko) * | 2006-02-08 | 2014-05-14 | 모르포테크, 인크. | 항원성 gm-csf 펩티드 및 gm-csf에 대한 항체 |
| KR101481844B1 (ko) | 2006-03-27 | 2015-01-13 | 메디뮨 리미티드 | Gm-csf 수용체에 대한 결합 성분 |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| US8679502B2 (en) | 2007-11-13 | 2014-03-25 | Evec Inc. | Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same |
| CA2717987C (en) | 2008-04-29 | 2018-11-13 | Micromet Ag | Inhibitors of gm-csf and il-17 for therapy |
| GB2476681B (en) | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
| EP3514169B1 (en) | 2010-11-26 | 2024-03-06 | Molecular Partners AG | Designed repeat proteins binding to serum albumin |
| BR112013033944A2 (pt) * | 2011-07-06 | 2017-12-19 | Morphosys Ag | combinação sinérgica |
| SG11201408196RA (en) | 2012-06-28 | 2015-03-30 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| CN104995210A (zh) | 2012-09-20 | 2015-10-21 | 莫弗系统股份公司 | 类风湿关节炎的治疗 |
| US9658228B2 (en) * | 2013-01-30 | 2017-05-23 | The Board of Trustees of the Leland University Junior University | Method to detect the onset and to monitor the recurrence of chronic graft versus host disease in transplantation patients |
| JP6490419B2 (ja) | 2014-12-24 | 2019-03-27 | 学校法人関西医科大学 | 制御性t細胞分化誘導剤 |
| US11655293B2 (en) | 2018-02-22 | 2023-05-23 | Universitat Zurich | Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT |
-
2019
- 2019-02-07 US US16/269,572 patent/US11655293B2/en active Active
- 2019-02-22 EP EP19705548.6A patent/EP3755715A1/en active Pending
- 2019-02-22 US US16/971,276 patent/US20210070851A1/en not_active Abandoned
- 2019-02-22 BR BR112020017253-7A patent/BR112020017253A2/pt not_active IP Right Cessation
- 2019-02-22 AU AU2019224550A patent/AU2019224550A1/en not_active Abandoned
- 2019-02-22 CA CA3091536A patent/CA3091536A1/en active Pending
- 2019-02-22 CN CN201980020251.7A patent/CN111886248B/zh active Active
- 2019-02-22 JP JP2020543999A patent/JP7278296B2/ja active Active
- 2019-02-22 WO PCT/EP2019/054493 patent/WO2019162472A1/en not_active Ceased
- 2019-02-22 MX MX2020008792A patent/MX2020008792A/es unknown
- 2019-02-22 MA MA051893A patent/MA51893A/fr unknown
- 2019-02-22 KR KR1020207025898A patent/KR20200123434A/ko not_active Ceased
-
2020
- 2020-08-21 MX MX2023001357A patent/MX2023001357A/es unknown
-
2023
- 2023-05-18 US US18/320,162 patent/US12384839B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190256587A1 (en) | 2019-08-22 |
| US20210070851A1 (en) | 2021-03-11 |
| AU2019224550A1 (en) | 2020-09-17 |
| MX2020008792A (es) | 2020-10-14 |
| US12384839B2 (en) | 2025-08-12 |
| RU2020129401A (ru) | 2022-03-22 |
| KR20200123434A (ko) | 2020-10-29 |
| EP3755715A1 (en) | 2020-12-30 |
| US20230340100A1 (en) | 2023-10-26 |
| JP7278296B2 (ja) | 2023-05-19 |
| CN111886248A (zh) | 2020-11-03 |
| US11655293B2 (en) | 2023-05-23 |
| MX2023001357A (es) | 2023-02-27 |
| BR112020017253A2 (pt) | 2020-12-22 |
| CN111886248B (zh) | 2025-03-04 |
| JP2021514368A (ja) | 2021-06-10 |
| RU2020129401A3 (cg-RX-API-DMAC7.html) | 2022-03-22 |
| CA3091536A1 (en) | 2019-08-29 |
| WO2019162472A1 (en) | 2019-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3755805A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF NON-AGE-RELATED HEARING DAMAGE IN AN INDIVIDUAL | |
| EP3873335A4 (en) | CHARACTERIZATION OF THERAPEUTIC EFFECTIVENESS OF NEUROSTIMULATION | |
| EP3802798A4 (en) | CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T) FOR TREATMENT OF CANCER | |
| EP3455205A4 (en) | PEPTIDOMIMETICS FOR TREATING A NOVOVIRUS INFECTION | |
| EP3641829A4 (en) | INTERFERON PRODRUG FOR TREATMENT OF CANCER | |
| EP3393475C0 (en) | CIFORADENT ALONE OR IN COMBINATION WITH ATEZOLIZUMAB FOR USE IN THE TREATMENT OF CANCER | |
| EP3616097A4 (en) | Dose reduction for medical imaging using deep convolutional neural networks | |
| EP3600281A4 (en) | COMBINATION THERAPY FOR TREATING OR PREVENTING TUMORS | |
| MA49131A (fr) | Utilisation d'antagonistes de klk5 pour le traitement d'une maladie | |
| MA50155A (fr) | Acides aminés à chaîne ramifiée pour le traitement d'une lésion neuronale | |
| EP3552611A4 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER WITH CRYSTALLINE TETRAARSEN HEXOXIDE POLYMORPH | |
| EP3814286A4 (en) | Continuous flow wastewater treatment system | |
| EP3778592A4 (en) | RADIOPHARMIC AGAINST PSMA FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | |
| EP3589307A4 (en) | REGENERATIVE FUNCTIONAL NEURONES TO TREAT NEURONAL INJURIES CAUSED BY CIRCUIT DISORDER | |
| EP3645044A4 (en) | USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, ELEMENT A5 ANTIBODIES TO TREAT GLAUCOMA | |
| EP3498362A4 (en) | DISK-LIKE FILTER MODULE FOR WATER TREATMENT AND FILTER ARRANGEMENT FOR WATER TREATMENT THEREFOR | |
| EP3861131A4 (en) | GENE THERAPY FOR THE TREATMENT OF PROPIONIC ACIDosis | |
| EP3846821A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF LIVER DISEASES | |
| EP3403675A4 (en) | ADENO-ASSOCIATED VIRUSVIRION FOR USE IN THE TREATMENT OF EPILEPSIA | |
| EP3432892A4 (en) | USEFUL MANNOSE-DERIVED ANTAGONISTS FROM FIMH FOR THE TREATMENT OF DISEASES | |
| EP3504204A4 (en) | INDAZOLYL-L, 2,4-THIADIAZOLAMINE AND RELATED COMPOUNDS FOR INHIBITING RHO-ASSOCIATED PROTEIN KINASES AND FOR TREATING DISEASES | |
| EP4069700A4 (en) | MACROCYCLES FOR USE IN TREATMENT OF DISEASES | |
| MA55490A (fr) | Mutéine de lipocaline pour le traitement de l'asthme | |
| MA43861A (fr) | Inhibiteurs il-8 destinés à être utilisés dans le traitement d'une neuropathie périphérique induite par une chimiothérapie | |
| EP3730144A4 (en) | AGENTS FOR TREATMENT OF DISEASES OF THE NERVOUS SYSTEM |